Drugs / Ilitacan
last change Mar 2026 re-read 2 minutes ago

Ilitacan

Developed for
pancreas disorder

Trials 0

Also used as a comparator or background therapy in 1 trial
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 4 NCT06368063 Comparator May 2024 → Mar 2026 overdue pancreas disorder Xi'an Jiaotong University Recruiting No outcome recorded

Evidence & citations 2 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as Ilitacan Ilitacan 150mg/m\^2 intravenous infusion for more than 30-90 minutes, day 1” NCT06368063
Route Intravenous “Ilitacan 150mg/m\^2 intravenous infusion for more than 30-90 minutes, day 1” NCT06368063